Legend Biotech (NASDAQ:AMTI) Earns Buy Rating from Analysts at BofA Securities

BofA Securities initiated coverage on shares of Legend Biotech (NASDAQ:AMTI) in a research note issued to investors on Tuesday, Briefing.com Automated Import reports. The brokerage issued a buy rating and a $34.00 price target on the stock.

Several other brokerages have also recently weighed in on AMTI. Bank of America started coverage on shares of Legend Biotech in a research report on Tuesday. They set a buy rating and a $34.00 price target on the stock. SVB Leerink started coverage on shares of Legend Biotech in a research report on Tuesday. They set an outperform rating and a $32.00 price target on the stock.

Shares of AMTI opened at $27.00 on Tuesday. Legend Biotech has a 52-week low of $17.05 and a 52-week high of $31.84.

About Legend Biotech

Applied Molecular Transport Inc develops biological therapeutics to treat autoimmune, metabolic, and inflammatory diseases.. The company develops submucosal biopharmaceuticals and bio-betters. Applied Molecular Transport Inc was incorporated in 2010 and is based in South San Francisco, California.

Featured Story: Dividend Achievers

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.